treatment of multiple metastases
play

Treatment of Multiple Metastases Steven Chmura, M.D., Ph.D. - PowerPoint PPT Presentation

Aug 06, 2023 •204 likes •1.57k views

A Trial Introduction to NRG-BR001: A Phase 1 Study of SBRT for the Treatment of Multiple Metastases Steven Chmura, M.D., Ph.D. Principal Investigator The University of Chicago NRG BR001: Talk Outline 1. Hypothesis & trial design 2.

  1. NRG BR001: Treatment planning guidelines • 3DCRT: – 7-13 static beams with zero-margin block-to-PTV margin – Rx isodose line = 60-90% (generally 80-90%) • VMAT: – Dynamic conformal arcs (>340 o ) • 3DCRT/IMRT/VMAT: – Hot spots within target (*) – Rx isodose volume/PTV volume = 1.2-1.5 – 50% isodose per Table 6-4 – Dose at 2cm from PTV per Table 6-4 * = indicates required planning goals

  2. NRG BR001: Dose Conformality for Single Target per RTOG 0813

  3. NRG BR001: Planning Priorities • 6.4.4 Planning Priorities • Every attempt should be made to successfully satisfy all of the planning goals and OAR criteria without deviation. In some circumstances, it may not be possible to meet all the ideal criteria leading to plans with an acceptable deviation. Thus, suggested priority of planning goals in order of importance is: 1. Respect spinal cord, cauda equina, sacral plexus and brachial plexus dose constraints. Meet dose “compactness” constraints including the prescription isodose surface 2. coverage, high dose spillage (location and volume), and intermediate dose spillage (D2cm, and R50%) as these define the “essence” of SBRT. Dose compactness should be assessed for plans based on treatment dose for a single lesion at a time. 3. Meet critical structure constraints other than those listed in 1. The OAR constraints are last in priority (except for nervous system tolerance), because they are the least validated. The “essence” of a stereotactic plan is captured mostly in the dose compactness criteria, thereby justifying their higher priority. As an example in a case where not all goals can be met, it would be suggested to meet dose compactness goals without deviation even at the expense of a non-spinal cord normal tissue having acceptable deviation. Unacceptable deviations should be avoided in all cases. 4. In cases where PTV coverage cannot be achieved while avoiding unacceptable deviations to OAR, coverage of a section of PTV including or immediately adjacent to the OAR may be as low as 70% of the prescription dose ONLY in this situation (see Section 6.5.4).

  4. NRG BR001: OAR constraints

  5. NRG BR001: Compliance Criteria

  6. Benchmark Planning

  7. BR001 Benchmark Case: Bilateral Adrenal Metastases Metastases Overlap with Parallel Organs RT GTV & PTV: LT GTV & PTV Overlap with liver

  8. BR001 Benchmark Case: Bilateral Adrenal Metastases Metastases Overlap with Parallel Organs LT GTV & PTV: Overlap with Kidney RT GTV & PTV

  9. BR001 Benchmark Case: Bilateral Adrenal Metastases Metastasis Overlap with Serial Organ LT GTV & PTV: Overlap with Stomach

  10. NRG BR001: FAQ

  11. NRG BR001: FAQ • Can my institution plan the benchmark with a single isocenter even though my institution has not yet credentialed to deliver treatment to 2 metastases using a single isocenter? – Yes • What should I do if an OAR is not in the structure set? – Contour it if you would like to use it for planning • What QA measurements are required? – None • Should the benchmark plan be reviewed by our physician? – Absolutely! To ensure it’s clinically acceptable

  12. NRG BR001: FAQ • If the plan is intended to treat both lesions simultaneously on the same day, am I required to submit separate dose grids for each lesion? – No (e.g., single VMAT plan) • For an IMRT/VMATplan, is a normalization of 60-90% required? – No, but ensure conformality is high • How should the conformality of the plan be assessed? – See Table 6-4 – 80% isodose should break up between 2 lesions

  13. NRG BR001: FAQ • I cannot meet the PTV coverage requirements while also meeting all the OAR constraints in Table 6-6. How should these competing constraints be balanced? – BR001 provides guidance on the “planning priorities” ( S ECTION 6.4.5): 1. Spinal dose constraints, as assessed on the composite dose map, must always be met. 2. PTV coverage may not fall below 70% of the 45 Gy prescription dose in regions overlapping with OAR. 3. No dose >47.25Gy may exist outside PTV. In addition, no dose >47.25Gy may exist in PTV volumes that overlap directly with OAR (e.g., Liver, Kidney_L, Stomach, Bowel). See S ECTIONS 6.4.3 & 6.5.4. – It is left to the discretion of the institution as to whether they will prioritize PTV coverage over OAR (e.g., stomach) constraints.

  14. NRG BR001: Benchmark Evaluation • How will the benchmark be evaluated? – Dose Volume Analysis (DVA) will be used to tabulate data – Composite dose will be used to evaluate all OAR constraints including 105% hotspot location – If each metastasis is planned for treatment on separate days, individual dose maps will be evaluated for PTV coverage

  15. NRG BR001: Dose Volume Analysis (DVA) for Benchmark Evaluation

  16. Benchmark Examples & Reviews

  17. NRG BR001: Benchmark Case 10 120% = 54 Gy 50% 110% = 49.5 Gy 105% = 47.25 Gy 70% 100% = 45 Gy 95% = 42.75 Gy 80% 90% = 40.5 Gy 80% = 36 Gy 95% 70% = 31.5 Gy 100% 50% = 22.5 Gy 25% = 11.25 Gy Did not pass.

  18. NRG BR001: Benchmark Case 10 120% = 54 Gy 110% = 49.5 Gy 105% = 47.25 Gy D2cm = Max Dose at 2cm from PTV > 90% 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Did not pass.

  19. NRG BR001: Benchmark Case 10 120% = 54 Gy 110% = 49.5 Gy 105% = 47.25 Gy 50% 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Did not pass.

  20. NRG BR001: Benchmark Case 10 120% = 54 Gy 110% = 49.5 Gy 105% = 47.25 Gy 50% 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Did not pass.

  21. NRG BR001: Benchmark Case 10 120% = 54 Gy 110% = 49.5 Gy 105% = 47.25 Gy 50% 100% = 45 Gy overlap 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Did not pass.

  22. NRG BR001: Benchmark Case 10 120% = 54 Gy 110% = 49.5 Gy 105% = 47.25 Gy 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Did not pass.

  23. NRG BR001: Benchmark Case 1 2 Isocenter Plan passed on 2 nd Try. Passed on 2 nd Try. Passed on 2 nd Try.

  24. NRG BR001: Benchmark Case 1 120% = 54 Gy 110% = 49.5 Gy 105% = 47.25 Gy 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Passed on 2 nd Try. 2 isocenters: passed on 2 nd try.

  25. NRG BR001: Benchmark Case 1 120% = 54 Gy 110% = 49.5 Gy 105% = 47.25 Gy 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy 2 isocenters: passed on 2 nd try.

  26. NRG BR001: Benchmark Case 1 120% = 54 Gy 110% = 49.5 Gy 105% = 47.25 Gy 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy 2 isocenters: passed on 2 nd try.

  27. NRG BR001: Benchmark Case 1 120% = 54 Gy 110% = 49.5 Gy 105% = 47.25 Gy 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy 2 isocenters: passed on 2 nd try.

  28. NRG BR001: Benchmark Case 1 120% = 54 Gy D2cm = Max Dose at 2cm from PTV > 70% 110% = 49.5 Gy 105% = 47.25 Gy 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy 2 isocenters: passed on 2 nd try.

  29. NRG BR001: Benchmark Case 15 120% = 54 Gy 110% = 49.5 Gy 105% = 47.25 Gy 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Passed on 1 st try using VMAT.

  30. NRG BR001: Benchmark Case 15 120% = 54 Gy 110% = 49.5 Gy 105% = 47.25 Gy 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Passed on 1 st try using VMAT.

  31. NRG BR001: Benchmark Case 15 120% = 54 Gy 110% = 49.5 Gy 105% = 47.25 Gy 100% = 45 Gy Priority = PTV 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Passed on 1 st try using VMAT.

  32. NRG BR001: Benchmark Case 6 120% = 54 Gy 110% = 49.5 Gy Priority = PTV 105% = 47.25 Gy 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Passed on 1 st try using VMAT.

  33. NRG BR001: Benchmark Case 3 120% = 54 Gy 110% = 49.5 Gy Priority = Stomach 105% = 47.25 Gy 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Passed on 1 st try using VMAT.

  34. NRG BR001: Benchmark Case 5 120% = 54 Gy 110% = 49.5 Gy Priority = Stomach 105% = 47.25 Gy 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Passed on 1 st try using VMAT.

  35. NRG BR001: Benchmark Case 12 120% = 54 Gy 110% = 49.5 Gy 105% = 47.25 Gy 90% connecting 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Passed on 2nd try using VMAT.

  36. NRG BR001: Benchmark Case 11 120% = 54 Gy 110% = 49.5 Gy 105% = 47.25 Gy 100% connecting 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Met DVA criteria but did not pass.

  37. NRG BR001: Benchmark Case 19 120% = 54 Gy 110% = 49.5 Gy 105% = 47.25 Gy 95% connecting 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Met DVA criteria but did not pass.

  38. NRG BR001: Benchmark Case 17 CyberKnife 120% = 54 Gy 110% = 49.5 Gy 105% = 47.25 Gy D2cm = Max Dose at 2cm from PTV > 85% 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy 95% of right PTV receives 48.6Gy  Unacceptable Deviation (< 42.5Gy or > 45.5Gy )

  39. NRG BR001: Benchmark Case 20 CyberKnife 120% = 54 Gy 110% = 49.5 Gy 105% = 47.25 Gy D2cm = Max Dose at 2cm from PTV = 80% 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Did not pass.

  40. NRG BR001: Benchmark Case 20 CyberKnife 120% = 54 Gy > 90% 110% = 49.5 Gy 105% = 47.25 Gy 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Did not pass.

  41. NRG BR001: Benchmark Case 20 CyberKnife 120% = 54 Gy > 80% 110% = 49.5 Gy 105% = 47.25 Gy 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Did not pass.

  42. NRG BR001: Benchmark Case 21 120% = 54 Gy CyberKnife 110% = 49.5 Gy 105% = 47.25 Gy D2cm = Max Dose at 2cm from PTV = 79% 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Passed on 1 st try.

  43. NRG BR001: Benchmark Case 21 120% = 54 Gy CyberKnife > 95% 110% = 49.5 Gy 105% = 47.25 Gy 100% = 45 Gy 95% = 42.75 Gy 90% = 40.5 Gy 80% = 36 Gy 70% = 31.5 Gy 50% = 22.5 Gy 25% = 11.25 Gy Passed on 1 st try.

  44. NRG BR001: Benchmark Statistics • As of Jan 28, 2015: – Benchmarks submitted = 22 – Benchmarks not passing but not yet re-submitted = 7 – Benchmarks passing = 15 • At 1 st attempt = 8 • At 2 nd attempt = 5 • At 3 rd attempt = 2 • Sites completed all credentialing = 9! • Satellites are required to submit benchmark.

  45. NRG BR001: Benchmark Statistics • Treatment strategy: – 1/15 treated with 2 separate plans to each lesion – 1/15 delivered with CyberKnife • Planning priorities: – 4/15 spared stomach – 11/15 treated PTV

  46. NRG BR001: Benchmark Statistics • PTV volume (LT + RT) = 103 cc • 95% dose volume = 128 cc (102-175) • 80% dose volume = 211 cc (164-346) • 70% dose volume = 279 cc (226-476) • 50% dose volume = 519 cc (416-872) • 105% dose volume = 39 cc (0-131) • Max dose at 2cm = 71% (58-88%)

  47. IGRT Credentialing Review

  48. NRG BR001: IGRT Credentialing

  49. NRG BR001: IGRT Credentialing

  50. NRG BR001: IGRT Credentialing • Purpose: – To assess whether positioning with image-guidance will ensure accurate PTV coverage • How is this accomplished? – Assess description of IGRT workflow including threshold for correction of translations & rotations – Assess image quality (technique, FOV) – Assess final treatment position relative to PTV margin required for protocol

  51. NRG BR001: IGRT Credentialing • Potential issues encountered with 3D registration: – Table movement prior to acquiring CBCT – Inter-observer variation

  52. NRG BR001: IGRT Credentialing • Recommended data for 2D IGRT: – 2D screenshots in addition to 2D DICOM images: • Reticule or scale • PTV contours • OAR contours (e.g., lung, spine) – 2D OBI screenshots at final treatment position helpful • Recommended data for 3D IGRT: – Screenshots of in-house registration between CBCT & planning CT • Reticule or scale • 3D blending/subtraction

  53. NRG BR001: 3D Spine IGRT Case 3 BrainLab ExacTrac

  54. NRG BR001: 3D Spine IGRT Case 3 OBI kV

  55. NRG BR001: 3D Spine IGRT Case 3 OBI kV

  56. NRG BR001: 3D Spine IGRT Case 3

  57. NRG BR001: 3D Spine IGRT Case 9

  58. NRG BR001: 3D Spine IGRT Case 9

  59. NRG BR001: 3D Spine IGRT Case 9

  60. NRG BR001: 3D Spine IGRT Case 9 Axis X Y Z Institution Shifts -8.0 1.0 2.0 Reviewer Shifts -5.6 1.5 1.0 Difference -2.4 0.5 1.0

  61. NRG BR001: 3D Spine IGRT Case 9 Axis X (mm) Y (mm) Z (mm) Institution’s Shifts -8.0 1.0 2.0 Reviewer’s Shifts -5.6 1.5 1.0 Difference -2.4 0.5 1.0 Rotational Differences < 2 degrees

  62. NRG BR001: 3D Spine IGRT Case 9

  63. NRG BR001: 3D Lung IGRT Case 9

  64. NRG BR001: 3D Lung IGRT Case 9

  65. NRG BR001: 3D Lung IGRT Case 9

  66. NRG BR001: 3D Lung IGRT Case 9

  67. NRG BR001: 3D Lung IGRT Case 9 Axis X (mm) Y (mm) Z (mm) Institution’s Shifts 2.3 -4.6 6.5 Reviewer’s Shifts 1.6 0.1 -5.2 Difference 0.7 -4.7 -1.3 Rotational Differences < 2 degrees

  68. NRG BR001: 3D Lung IGRT Case 9

  69. Available Resources & Guidelines

Recommend

Benchmark &amp; FAQ for NRG BR001: A Phase 1 Study of SBRT for the Treatment of Multiple

Benchmark &amp; FAQ for NRG BR001: A Phase 1 Study of SBRT for the Treatment of Multiple

Benchmark &amp; FAQ for NRG BR001: A Phase 1 Study of SBRT for the Treatment of Multiple Metastases Credentialing Requirements (S ECTION 5) Facility Questionnaire Benchmark planning 3DCRT IMRT SBRT IGRT credentialing credentialing

557 views • 55 slides
Management of Brain Metastases Palliative Care Conference: Oncology Update 13/10/17 Dr Lauren

Management of Brain Metastases Palliative Care Conference: Oncology Update 13/10/17 Dr Lauren

Management of Brain Metastases Palliative Care Conference: Oncology Update 13/10/17 Dr Lauren Gorf Lauren.gorf@poole.nhs.uk Introduction Brain metastases account for &gt;1/2 of all intracranial tumours Approaches to treatment:

404 views • 28 slides
Synchronous Colorectal Liver Colorectal Cancer with Hepatic Metastases: The Primary Should be

Synchronous Colorectal Liver Colorectal Cancer with Hepatic Metastases: The Primary Should be

Synchronous Colorectal Liver Colorectal Cancer with Hepatic Metastases: The Primary Should be Metastases Resected First Approximately 20% to 30% will have liver-only metastases on initial evaluation. Synchronous Metastasis: Definition

438 views • 4 slides
Multivariate Analysis of treatment in Multiple Sclerosis using the Wei-Lachin procedure Thomas

Multivariate Analysis of treatment in Multiple Sclerosis using the Wei-Lachin procedure Thomas

Multivariate Analysis of treatment in Multiple Sclerosis using the Wei-Lachin procedure Thomas Zwingers CROS DE GmbH Augsburg, Germany Multivariate Analysis of treatment in MS using the Wei-Lachin procedure The problem Multiple

239 views • 9 slides
Brain Metastasis Segmentation Network Trained with Robustness to Annotations with Multiple False

Brain Metastasis Segmentation Network Trained with Robustness to Annotations with Multiple False

Brain Metastasis Segmentation Network Trained with Robustness to Annotations with Multiple False Negatives MIDL 2020 P APER #48 (P OSTER ) Darvin Yi, Endre Grovik, Michael Iv, Elizabeth Tong, Greg Zaharchuk, Daniel Rubin Brain Metastases

370 views • 8 slides
Management of Patients with Her2+ve Brain metastases Her2+ve patients 15% of all breast cancer

Management of Patients with Her2+ve Brain metastases Her2+ve patients 15% of all breast cancer

Management of Patients with Her2+ve Brain metastases Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not cross BBB Management dependent on number of metastases Patients

583 views • 17 slides
INVESTORS PRSENTATION CONFIDENTIAL THE EXCELLENCE OF CERAMICS FOR THE TREATMENT OF BONE

INVESTORS PRSENTATION CONFIDENTIAL THE EXCELLENCE OF CERAMICS FOR THE TREATMENT OF BONE

INVESTORS PRSENTATION CONFIDENTIAL THE EXCELLENCE OF CERAMICS FOR THE TREATMENT OF BONE INFECTIONS AND BONE METASTASES I.CERAM | Investors Presentation | 18 and 19 th April 2017 CONFIDENTIAL Andr KERISIT Chairman and Founder of I.CERAM

593 views • 27 slides
treatment in active relapsing remitting multiple sclerosis : A study of real world evidence

treatment in active relapsing remitting multiple sclerosis : A study of real world evidence

Efficacy of alemtuzumab treatment in active relapsing remitting multiple sclerosis : A study of real world evidence ------------------------------ Mentor: Dr. Ofir Zmira Student: Alex Halpern Multiple Sclerosis Alemtuzumab Monoclonal

280 views • 9 slides
Oncology Conference New Treatment Paradigms in Relapsed/Refractory Multiple Myeloma: Integrating

Oncology Conference New Treatment Paradigms in Relapsed/Refractory Multiple Myeloma: Integrating

2020 Spring Oncology Conference New Treatment Paradigms in Relapsed/Refractory Multiple Myeloma: Integrating Novel Agents Into Clinical Practice Learning Objectives Identify novel agents used in the treatment of relapsed/refractory (RR)

951 views • 49 slides
Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2):

Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2):

Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo- controlled, randomised trial Massimo Imazio, MD, FESC on behalf of the CORP-2 Investigators Cardiology

470 views • 20 slides
Cognitive challenges in treatment trials for epilepsy and multiple sclerosis Do Regulatory

Cognitive challenges in treatment trials for epilepsy and multiple sclerosis Do Regulatory

ISCTM-ECNP Joint Autumn Conference 6 September 2019 Copenhagen, Denmark Regulatory Perspective on Cognitive challenges in treatment trials for epilepsy and multiple sclerosis Do Regulatory Guidelines address need? Efficacy

563 views • 17 slides
IMMUNOTHERAPY AND RADIOTHERAPY FOR MELANOMA BRAIN METASTASES: IS THERE A SYNERGISM? Di Brina

IMMUNOTHERAPY AND RADIOTHERAPY FOR MELANOMA BRAIN METASTASES: IS THERE A SYNERGISM? Di Brina

IMMUNOTHERAPY AND RADIOTHERAPY FOR MELANOMA BRAIN METASTASES: IS THERE A SYNERGISM? Di Brina L.*, Franceschini D.*, Navarria P.*, Ascolese AM.*, DAgostino GR.*, Franzese C.*, De Rose F.*, Comito T.*, Iftode C.*, Tozzi A.*, Palumbo V.*,

350 views • 17 slides
Single Ventricle BUT Multiple PH treatment in Single Ventricule Ventricular function:

Single Ventricle BUT Multiple PH treatment in Single Ventricule Ventricular function:

3/9/2019 Single Ventricle BUT Multiple PH treatment in Single Ventricule Ventricular function: LV? RV? Atrial pressure : AV valve ? Pulmonary circulation ? Marilyne Lvy, Necker- Paris - France UCSF from 2016 to 2019

245 views • 12 slides
Management of Regional Lymphatic Metastases for Cutaneous Melanoma: Early Intervention is Best

Management of Regional Lymphatic Metastases for Cutaneous Melanoma: Early Intervention is Best

Management of Regional Lymphatic Metastases for Cutaneous Melanoma: Early Intervention is Best John E Mullinax, MD, FACS Assistant Member, Surgical Oncology Moffitt Cancer Center FL Chapter, American College of Surgeons Annual Meeting,

574 views • 20 slides
Piloting and Sizing Sequential Multiple Assignment Randomized Trials in Dynamic Treatment Regime

Piloting and Sizing Sequential Multiple Assignment Randomized Trials in Dynamic Treatment Regime

Piloting and Sizing Sequential Multiple Assignment Randomized Trials in Dynamic Treatment Regime Development Advances in Interdisciplinary Statistics and Combinatorics October 6, 2012University of North Carolina Greensboro Daniel Almirall

553 views • 24 slides
Synergy between Proteasome Inhibitors and IMiDs for the treatment of Multiple Myeloma Pr Philippe

Synergy between Proteasome Inhibitors and IMiDs for the treatment of Multiple Myeloma Pr Philippe

Synergy between Proteasome Inhibitors and IMiDs for the treatment of Multiple Myeloma Pr Philippe Moreau University Hospital, Nantes, France Date of preparation: April 2016 Job code: GLO/IXA/2016-00003k Synergy between Pis and IMiDs was first

819 views • 56 slides
Treatment of Multiple Sclerosis Applicant Town Hall October 11, 2016 Agenda Welcome

Treatment of Multiple Sclerosis Applicant Town Hall October 11, 2016 Agenda Welcome

Treatment of Multiple Sclerosis Applicant Town Hall October 11, 2016 Agenda Welcome Introduction to PCORI Background for the PFA Programmatic Requirements for this PFA Administrative Requirements for this PFA Resources Submit questions via

645 views • 40 slides
Treatment of Multiple Sclerosis LOI Applicant Town Hall October 22, 2015 Agenda Welcome

Treatment of Multiple Sclerosis LOI Applicant Town Hall October 22, 2015 Agenda Welcome

Treatment of Multiple Sclerosis LOI Applicant Town Hall October 22, 2015 Agenda Welcome Introduction to PCORI Background for the PFA Programmatic Requirements for this PFA Administrative Requirements for this PFA Resources Submit questions

669 views • 46 slides
Phylogenies Derived from Matched Transcriptome in Breast Cancer Brain Metastases Yifeng Tao 1,2 ,

Phylogenies Derived from Matched Transcriptome in Breast Cancer Brain Metastases Yifeng Tao 1,2 ,

Phylogenies Derived from Matched Transcriptome in Breast Cancer Brain Metastases Yifeng Tao 1,2 , Haoyun Lei 1,2 , Adrian V. Lee 3 , Jian Ma 1 , Russell Schwartz 1,4 1 Computational Biology Department, School of Computer Science, Carnegie Mellon

321 views • 14 slides
Novel Ways to Target and Develop Therapies for Cancer Metastases: Stop Spreading the New

Novel Ways to Target and Develop Therapies for Cancer Metastases: Stop Spreading the New

Novel Ways to Target and Develop Therapies for Cancer Metastases: Stop Spreading the New Moderator: Joel S. Sandler , PhD, Associate Principal, Cello Health BioConsulting, previously Defined Health Panelists: Yibin Kang , PhD,

372 views • 10 slides
Interesting case report Cutaneous metastases from primary carcinoma larynx - A rare

Interesting case report Cutaneous metastases from primary carcinoma larynx - A rare

ISSN: 2250-0359 Volume 3 Issue 2 2013 Interesting case report Cutaneous metastases from primary carcinoma larynx - A rare presentation Ramesh Aravamuthan, Ratnavel Gurusamy,

467 views • 7 slides
Group sequential designs for Clinical Trials with multiple treatment arms Susanne Urach, Martin

Group sequential designs for Clinical Trials with multiple treatment arms Susanne Urach, Martin

Group sequential designs for Clinical Trials with multiple treatment arms Susanne Urach, Martin Posch Vienna, October 7, 2015 This project has received funding from the European Unions Seventh Framework Programme for research, technological

492 views • 34 slides
Group sequential designs for Clinical Trials with multiple treatment arms Susanne Urach, Martin

Group sequential designs for Clinical Trials with multiple treatment arms Susanne Urach, Martin

Group sequential designs for Clinical Trials with multiple treatment arms Susanne Urach, Martin Posch Cologne, June 26, 2015 This project has received funding from the European Unions Seventh Framework Programme for research, technological

339 views • 33 slides
Emerging Treatment Options for Relapsed / Refractory Multiple Myeloma William Bensinger, MD

Emerging Treatment Options for Relapsed / Refractory Multiple Myeloma William Bensinger, MD

Emerging Treatment Options for Relapsed / Refractory Multiple Myeloma William Bensinger, MD Myeloma &amp; Transplant Program Swedish Cancer Institute Seattle, WA Outline Targeting apoptosis Venetoclax Targeting BCMA CAR T

929 views • 25 slides

More recommend